(RTTNews) - Altimmune, Inc.(ALT), a developer of novel peptide-based therapeutics for liver and metabolic diseases, said on Monday that its Chief Executive Officer, Vipin Garg, will step down with effect from January 1, 2026.
Subsequently, the company's Chairman, Jerry Durso, will assume the role of CEO in addition to his current responsibility as Chairman.
Durso was appointed to Altimmune's Board in February and was named Chairman of the Board in August.
Earlier, Durso had served as the CEO of Intercept Pharmaceuticals Inc. (ICPT), a company focused on liver diseases. Prior to his role at Intercept, Durso spent over two decades at Sanofi SA (SNY, SAN.PA, SNYNF).
ALT was down by 4.75% at $5.01 in the pre-market trade on the Nasdaq.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
